Central banks in UK, Europe and the US all set to raise rates
|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's range||173.80 - 180.21|
|52-week range||115.03 - 217.25|
|Beta (5Y monthly)||1.71|
|PE ratio (TTM)||6.64|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The bad news is Moderna's vaccine may not be able to replicate these levels in a post-pandemic environment. The good news is the vaccine still could lead to significant blockbuster revenue -- and that will support the development of Moderna's late-stage pipeline. As a result, Moderna could launch other potential blockbusters over the next few years.
Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.